TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
+6.33%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$209M
AUM Growth
+$209M
(-14%)
Cap. Flow
-$37.6M
Cap. Flow
% of AUM
-17.99%
Top 10 Holdings %
Top 10 Hldgs %
55.71%
Holding
58
New
10
Increased
11
Reduced
19
Closed
13
Top Buys
| 1 |
Cigna
CI
|
$16.1M |
| 2 |
Merck
MRK
|
$6.97M |
| 3 |
Exelixis
EXEL
|
$4.53M |
| 4 |
Gilead Sciences
GILD
|
$4.46M |
| 5 |
Cerus
CERS
|
$3.57M |
Top Sells
| 1 |
Tenet Healthcare
THC
|
$10.7M |
| 2 |
Humana
HUM
|
$9.28M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$7.95M |
| 4 |
STRM
Streamline Health Solutions
STRM
|
$7.35M |
| 5 |
Lantheus
LNTH
|
$5.81M |
Sector Composition
| 1 | Healthcare | 90.77% |
| 2 | Consumer Staples | 3.25% |
| 3 | Technology | 0.7% |
| 4 | Consumer Discretionary | 0% |
| 5 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Cigna
CI
$80.3B
| $18M | 8.5% | 75,000 +67,000 | +838% | +$16.1M |
|
2
Pacira BioSciences
PCRX
$1.2B
| $15.6M | 7.4% | 205,000 -35,000 | -15% | -$2.67M |
|
|
3
Lantheus
LNTH
$3.73B
| $13.8M | 6.54% | 250,000 -105,000 | -30% | -$5.81M |
|
|
4
Merck
MRK
$210B
| $12.7M | 6.02% | 155,000 +85,000 | +121% | +$6.97M |
|
5
Bioventus
BVS
$495M
| $11.6M | 5.5% | 825,001 -49,999 | -6% | -$705K |
|
6
SI-BONE Inc
SIBN
$719M
| $10.7M | 5.08% | 475,000 -75,000 | -14% | -$1.7M |
|
7
Rigel Pharmaceuticals
RIGL
$697M
| $9.72M | 4.6% | 3,250,000 -1,250,000 | -28% | -$3.74M |
|
|
8
Cerus
CERS
$251M
| $9.06M | 4.29% | 1,650,000 +650,000 | +65% | +$3.57M |
|
9
Medtronic
MDT
$119B
| $8.32M | 3.94% | 75,000 -50,000 | -40% | -$5.55M |
|
10
AngioDynamics
ANGO
$417M
| $6.89M | 3.26% | 320,000 -25,000 | -7% | -$539K |
|
11
Turning Point Brands
TPB
$1.79B
| $6.8M | 3.22% | 200,000 -50,000 | -20% | -$1.7M |
|
|
12
Tenet Healthcare
THC
$16.3B
| $6.45M | 3.05% | 75,000 -125,000 | -63% | -$10.7M |
|
|
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.23M | 2.95% | 370,000 +145,000 | +64% | +$2.44M |
|
14
CVS Health
CVS
$92.8B
| $5.06M | 2.39% | 50,000 +10,000 | +25% | +$1.01M |
|
15
InMode
INMD
$944M
| $4.8M | 2.27% | 130,000 +85,000 | +189% | +$3.14M |
|
16
Jazz Pharmaceuticals
JAZZ
$7.75B
| $4.67M | 2.21% | 30,000 +5,000 | +20% | +$778K |
|
17
Phreesia
PHR
$1.88B
| $4.61M | 2.18% | 175,000 +100,000 | +133% | +$2.64M |
|
|
18
Exelixis
EXEL
$10.1B
| $4.53M | 2.15% | +200,000 | New | +$4.53M |
|
|
MDRX
19
DELISTED
Veradigm Inc. Common Stock
MDRX
| $4.5M | 2.13% | 200,000 | – | – |
|
|
20
Gilead Sciences
GILD
$140B
| $4.46M | 2.11% | +75,000 | New | +$4.46M |
|
21
Henry Schein
HSIC
$8.44B
| $4.36M | 2.06% | 50,000 +13,000 | +35% | +$1.13M |
|
22
AtriCure
ATRC
$1.84B
| $4.27M | 2.02% | 65,000 -35,000 | -35% | -$2.3M |
|
23
Tactile Systems Technology
TCMD
$297M
| $2.48M | 1.17% | +122,756 | New | +$2.48M |
|
24
Viatris
VTRS
$12.3B
| $2.45M | 1.16% | 225,000 -275,000 | -55% | -$2.99M |
|
|
VRAY
25
DELISTED
ViewRay, Inc.
VRAY
| $2.35M | 1.11% | 600,000 -600,000 | -50% | -$2.35M |
|